Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Prism Biolab Co. Ltd. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 2 distinct art units. The prosecution involves the distinct examiner HUI, SAN MING R, who is also the busiest examiner and accounts for 1 pending office action. The data shows that the 2 pending actions are split between different examiners and art units.
The Biotechnology & Pharmaceuticals focus remains consistent across the portfolio, even as the matters are handled by separate examiners. Having 2 pending office actions in 2 distinct art units suggests that the company is pursuing multiple technical avenues within its field. Practitioners should be prepared to manage different examiner preferences while maintaining a unified strategy. The presence of HUI, SAN MING R as the busiest examiner with 1 pending office action indicates an even distribution of the current workload. This decentralized approach can help the company navigate the USPTO more effectively by engaging with multiple divisions. The legal team should monitor both art units for any diverging trends that could impact the prosecution of the 2 pending matters.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUI, SAN MING R | 1 | 59.6% | +20.0% |
| RICCI, CRAIG D | 1 | 53.7% | +52.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18273064 | NOVEL BICYCLIC COMPOUNDS | HUI, SAN MING R | — |
| 18030328 | NOVEL BICYCLIC COMPOUNDS | RICCI, CRAIG D | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| 1611 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18273064 | NOVEL BICYCLIC COMPOUNDS | HUI, SAN MING R | 1627 | §103 | Non-Final OA | — | Pending | Jul 19, 2023 |
| 18030328 | NOVEL BICYCLIC COMPOUNDS | RICCI, CRAIG D | 1611 | §103 | Final Rejection | — | Pending | Apr 05, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPrism Biolab Co. Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
San Ming R Hui has the most, with 1 of Prism Biolab Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
